UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.
IUPAC name: (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
Purity: 99,8% min
Appearance: white powder
The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic purposes.